High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer

High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer

Abstract Background and objectives We explored the prognostic usefulness of the pan-immune-inflammation value (PIV) in patients with stage IIIB/C non-small-cell lung cancer (NSCLC) who underwent concurrent chemoradiotherapy (CCRT). Methods and patients For all patients, the PIV was calculated using...

Full description

Bibliographic Details
Main Authors: Erkan Topkan, Ahmet Kucuk, Emine Elif Ozkan, Duriye Ozturk, Ali Ayberk Besen, Huseyin Mertsoylu, Berrin Pehlivan, Ugur Selek
Format: Article
Language:English
Published: Springer 2023-12-01
Series:Discover Oncology
Subjects:
Non-small-cell lung cancer
Inflammation
Biological marker
Pan-immune-inflammation value
Prognosis survival
Online Access:https://doi.org/10.1007/s12672-023-00851-8

Internet

https://doi.org/10.1007/s12672-023-00851-8

Similar Items